Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02219321 · ClinicalTrials.gov registry record · Phase 3
Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT02219321 is a Phase 3 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT02219321, a Phase 3 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
Prescription drug abuse represents a major healthcare problem, with treatment costs reaching billions of dollars annually in the United States alone. Today opioids are commonly prescribed for chronic non-cancer pain and are only partially effective for short-term pain relief. Whereas opioids are initially part of the solution for pain, it eventually often turns to be a problem in patient with chronic pain. Long-term treatment with opioids can be complicated by development of tolerance, dependency, addiction, abnormal pain sensitivity, hormonal changes, and immune modulation. Unfortunately, the chronic use of anti-inflammatory drugs is associated with a marked increase in adverse effects. The purpose of this study is to determine whether systemic administration of lidocaine provides effective pain relief in opioid dependent chronic pain patients. Investigators intend to demonstrate that lidocaine infusion can improve pain relief and physical function in opioid dependent patients, thus improving compliance and patient satisfaction, which may potentially help wean patients off narcotics. The long-term goal of this proposal is to decrease opioid dependence in chronic pain patients by using lidocaine infusion.
Interventions
- DRUG Saline infusion
- DRUG Lidocaine infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02219321
The ClinicalTrials.gov registry entry for NCT02219321 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline infusion is the first listed.
NCT02219321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02219321 about?
NCT02219321 is a clinical study titled "Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients". Prescription drug abuse represents a major healthcare problem, with treatment costs reaching billions of dollars annually in the United States alone. Today opioids are commonly prescribed for chronic non-cancer pain and are only partially effective for short-term pain relief. Whereas opioids are ini...
What is the current status of trial NCT02219321?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2014-12. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT02219321?
The interventions under investigation include: Saline infusion (DRUG), Lidocaine infusion (DRUG).
Who is sponsoring clinical trial NCT02219321?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.